The short to medium term benefits of the Australian colorectal cancer screening program

Sasha Taylor[1], Farhad Salimi[1], Arul Earnest[1], Alexander G Heriot[2,3], John R Zalcberg[1], Susannah Ahern[1,4]

In Australia, colorectal cancer is the second most frequently diagnosed cancer and one of the most common causes of cancer-related death.[1] Evidence that bowel cancer screening reduces mortality through early detection and treatment[2] led to the introduction in 2006 of the Australian National Bowel Cancer Screening Program (NBCSP), offering faecal occult blood testing. The NBCSP has been progressively rolled out, from covering those aged 55 or 65 years in 2006 to screening every two years for all Australians aged 50–74 years by 2020.[3] During 2016–17, 41% of people invited to participate in screening did so.[4] A recent review of the NBCSP found that the risk of death from colorectal cancer was lower for invitees, and that those who had cancer were diagnosed at an earlier stage of disease.[5]

In Australia, jurisdictional cancer registries do not collect data on surgery-related morbidity. However, the Binational Colorectal Cancer Audit (BCCA) (https://www.bowelcanceraudit.com) has collected information since 2007 on the diagnosis, management, and outcomes of surgically managed Australian and New Zealand patients with colorectal cancer, as well as whether patients were identified by the NBCSP. BCCA data are voluntarily collected by 435 registered surgeons at 138 participating hospitals across Australia and New Zealand, covering about 24% of

1 Demographic and clinical features of 15 730 patients who underwent surgery for colorectal cancer in Australia, 2007–2018, by diagnostic pathway

Characteristic	Total	Identification of patients		P
		NBCSP	Other	
Number of patients	15 730	1357	14 373	
Age at surgery (years)				
Mean (SD)	69 (13)	64 (7)	69 (14)	< 0.001
Range	18–100	50–75	18–100	
50 or under*	1556 (10%)	77 (6%)	1479 (10%)	
51–60	2433 (15%)	385 (28%)	2048 (14%)	
61–70	4192 (27%)	651 (48%)	3541 (25%)	
71–80	4473 (28%)	244 (18%)	4229 (29%)	
over 80	3073 (20%)	0	3073 (21%)	
Missing data	3	0	3	
Sex				0.003
Women	7142 (45%)	563 (42%)	6579 (46%)	
Men	8586 (55%)	792 (58%)	7794 (54%)	
Missing data	2	2	0	
American Society of Anesthesiologists score				< 0.001
1–2 (low risk)	9205 (60%)	1000 (77%)	8205 (59%)	
3–5 (high risk)	6033 (40%)	294 (23%)	5739 (41%)	
Missing data	492	63	429	
Socio-economic status (IRSD quintile)				< 0.001
1 (most disadvantaged)	2470 (16%)	224 (17%)	2246 (16%)	
2	2385 (16%)	221 (17%)	2164 (16%)	
3	2957 (20%)	278 (22%)	2679 (19%)	
4	3107 (21%)	288 (22%)	2819 (20%)	
5 (least disadvantaged)	4153 (28%)	282 (22%)	3871 (28%)	
Missing data	658	64	594	

[1]School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC. [2]Epworth HealthCare, Melbourne, VIC. [3]Peter MacCallum Cancer Institute, Melbourne, VIC. [4]University of Melbourne, Melbourne, VIC. ✉ susannah.ahern@monash.edu • doi: 10.5694/mja2.50859

1 Continued

| Characteristic | Total | Identification of patients | | P |
		NBCSP	Other	
Cancer type				0.50
Colon	11 287 (72%)	963 (71%)	10 324 (72%)	
Rectal	4443 (28%)	394 (29%)	4049 (28%)	
Operative urgency				< 0.001
Elective	13 457 (86%)	1310 (96%)	12 147 (85%)	
Emergency	999 (6%)	11 (1%)	988 (7%)	
Urgent	1248 (8%)	36 (2%)	1212 (8%)	
Missing data	26	0	26	
Cancer stage				< 0.001
0 (cancer *in situ*)	699 (5%)	92 (7%)	607 (4%)	
I (local disease)	3728 (24%)	535 (41%)	3193 (23%)	
II (local disease)	4689 (31%)	278 (21%)	4411 (32%)	
III (nodal spread)	4437 (29%)	347 (26%)	4090 (29%)	
IV (metastatic disease)	1625 (11%)	42 (3%)	1583 (11%)	
X (not identifiable)	121 (1%)	16 (1%)	105 (1%)	
Missing data	431	47	384	
Operative approach				< 0.001
Minimally invasive surgery[†]	10 498 (67%)	1082 (80%)	9416 (66%)	
Open	5140 (33%)	269 (20%)	4871 (34%)	
Missing data	92	6	86	

IRSD = Index of Relative Socioeconomic Disadvantage (Australian Bureau of Statistics); NBCSP = National Bowel Cancer Screening Program; SD = standard deviation. *National screening program participants are aged 50 years or more. †Laparoscopic, hybrid, conversion of laparoscopic, robotic and transanal total mesorectal excision. ◆

2 Logistic and linear regression analysis of the association between screening and outcomes for 11 366 patients with colorectal cancer, Australia, 2007–2018

| Outcome | Identification of patients | | NBCSP *v* other | |
	NBCSP	Other	Univariate regression: OR (95% CI)	Multivariate regression: aOR* (95% CI)
Number of patients	843	10 523		
30-day mortality[†]	2	175	0.14 (0.02–0.44)	0.31 (0.05–1.01)
Surgical complications[‡]	171	2494	0.82 (0.69–0.97)	0.83 (0.69–0.99)
Medical complications[§]	89	1889	0.54 (0.43–0.67)	0.75 (0.59–0.94)
Returned to theatre	52	658	0.99 (0.73–1.31)	1.02 (0.75–1.37)
			Mean difference (95% CI)	**Adjusted mean difference* (95% CI)**
Length of stay (days), mean (SD)	7.27 (6.17)	9.62 (8.02)	–2.34 (–2.90 to –1.79)	–1.56 (–2.06 to –1.06)

aOR = adjusted odds ratio; CI = confidence interval; NBCSP = National Bowel Cancer Screening Program; OR = odds ratio; SD = standard deviation. * Adjusted for age, sex, socio-economic status, screen category, cancer type, American Society of Anesthesiologists score. † Within 30 days of surgery. ‡ Abdominal/pelvic collection, anastomotic leak, entero-cutaneous fistula, wound dehiscence, wound infection, sepsis, ileus, small bowel obstruction, urinary retention, ureteric injury, splenectomy, post-operative haemorrhage. § Including chest infection, cardiac complications, deep vein thrombosis, pulmonary embolus. ◆

newly diagnosed cases of colorectal cancer in 2019.[6] We sought to determine whether patients with surgically managed colorectal cancer diagnosed through the NBCSP have better post-operative outcomes than those diagnosed in other pathways.

We undertook a cross-sectional analysis of de-identified BCCA data for patients aged 18 years or over who underwent surgery in

Australia for colorectal cancer during January 2007 – December 2018. Outcome measures were inpatient and 30-day mortality; surgical complications; medical complications; return to theatre; and hospital length of stay. We undertook binary logistic regression to assess associations between screening and binary outcomes. The association with length of stay was assessed in ordinary least squares linear regression models. The Monash

University Human Research Ethics Committee (project, 19327) and the BCCA Operations Committee provided ethics approval for our study.

Of 23 310 cases of colorectal cancer in the database, we could include 15 630 cases with data on cancer type and screening status in our comparison of demographic and clinical characteristics. A larger proportion of patients identified by the NBCSP than of otherwise identified patients were men (58% *v* 54%); their mean age (64 years, standard deviation [SD], 7 years *v* 69 years; SD, 14 years) was lower, and larger proportions had American Society of Anesthesiologists (ASA) scores in the low risk range (77% *v* 59%), were from lower socio-economic status areas, had presented for elective surgery (96% *v* 85%), had less advanced cancer stage disease (stages 0–II: 69% *v* 63%), and underwent minimally invasive surgery (80% *v* 66%) (Box 1).

Data on adjusting variables and outcomes were available for the 11 366 cases included in our logistic regression models. NBCSP-detected patients were less likely to have post-operative surgical (adjusted odds ratio [aOR], 0.83; 95% confidence interval [CI], 0.69–0.99) or medical complications (aOR, 0.75; 95% CI, 0.59–0.94); their length of stay was also briefer (adjusted mean difference, –1.56 days; 95% CI, –2.06 to –1.06 days). Post-operative mortality and return to theatre rates were similar for screened and other patients (Box 2).

Our analysis of BCCA data indicates that, in addition to the lower long term mortality associated with the NBCSP,[5] short term post-operative benefits are also evident that should be taken into account when promoting the program. Our study reinforces calls to improve participation rates in the national screening program by eligible participants to optimise the value of this critically important initiative.

Competing interests: No relevant disclosures. ■

1 Australian Institute of Health and Welfare. Cancer in Australia 2017 (Cat. no. CAN 100; Cancer series no. 101). Canberra: AIHW, 2017.

2 Hewitson P, Glasziou P, Irwig L, et al. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. *Cochrane Database Syst Rev* 2007; CD001216.

3 Australian Department of Health. National Bowel Cancer Screening Program: policy framework phase four (2015–2020). Nov 2017. http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/CDD8E9C8B95B9C94CA25806A007B6046/$File/Policy%20Framework%2014112017_KB.pdf (viewed Sept 2020).

4 Australian Institute of Health and Welfare. National Bowel Cancer Screening Program: monitoring report 2019 (Cat. no. CAN 125; Cancer series no. 125). Canberra: AIHW, 2019.

5 Australian Institute of Health and Welfare. Analysis of bowel cancer outcomes for the National Bowel Cancer Screening Program (Cat. no. CAN 113). Canberra: AIHW, 2018.

6 Dagher H, Ahern S, Salimi F, et al. The 2019 data bi-national colorectal cancer audit report. May 2020. https://static1.squarespace.com/static/5dcb9934d3d5c2516c2ff339/t/5ecd9c82fd31365e4f20baec/1590533311233/BCCA+Annual+Report+2020+%5B2019+Data%5D.pdf (viewed Sept 2020). ■